Skip to main content

Published locations for Phase 3 trial supports long-term efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Phase 3 trial supports long-term efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis

User login

  • Reset your password
  • /content/phase-3-trial-supports-long-term-efficacy-and-safety-abrocitinib-moderate-severe-atopic
  • /dermatology/article/264333/atopic-dermatitis/phase-3-trial-supports-long-term-efficacy-and-safety